首页> 美国卫生研究院文献>Arthritis Research >Apoptosis is not the major death mechanism induced by celecoxib on rheumatoid arthritis synovial fibroblasts
【2h】

Apoptosis is not the major death mechanism induced by celecoxib on rheumatoid arthritis synovial fibroblasts

机译:凋亡不是塞来昔布对类风湿关节炎滑膜成纤维细胞诱导的主要死亡机制

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Synovial hyperplasia in rheumatoid arthritis (RA) has been associated with apoptosis deficiency of RA fibroblast-like synoviocytes (FLSs). Celecoxib is a non-steroidal anti-inflammatory drug that has been demonstrated to induce apoptosis in some cellular systems. We have therefore examined the dose- and time-dependent effects of celecoxib on RA FLS viability. Treatment of RA FLSs with celecoxib for 24 hours reduced their viability in a dose-dependent manner. Analysis of celecoxib-treated RA FLSs for their content of apoptotic and necrotic cells by Annexin V staining and TO-PRO-3 uptake displayed only few apoptotic cells. Caspase 3, a key mediator of apoptosis, was not activated in celecoxib-treated RA FLSs, and the presence of specific caspase 3 or pan-caspase inhibitors did not affect celecoxib-induced cell death. Moreover, we could not detect other signs of apoptosis, such as cleavage of poly(ADP-ribose) polymerase, caspase 8 or 9, or DNA fragmentation. We therefore conclude that apoptosis is not the major death pathway in celecoxib-treated RA FLSs.
机译:类风湿关节炎(RA)中的滑膜增生与RA成纤维样滑膜细胞(FLSs)的细胞凋亡不足有关。塞来昔布是一种非甾体类抗炎药,已被证明在某些细胞系统中诱导细胞凋亡。因此,我们检查了塞来昔布对RA FLS生存力的剂量依赖性和时间依赖性。用塞来昔布治疗RA FLS 24小时以剂量依赖性方式降低了它们的生存能力。通过膜联蛋白V染色和TO-PRO-3摄取分析塞来昔布处理的RA FLS的凋亡和坏死细胞含量,仅显示少数凋亡细胞。 Caspase 3是细胞凋亡的关键介体,在塞来昔布治疗的RA FLS中未激活,并且特定caspase 3或pan-caspase抑制剂的存在不影响celecoxib诱导的细胞死亡。此外,我们无法检测到其他凋亡迹象,例如聚(ADP-核糖)聚合酶,胱天蛋白酶8或9的裂解或DNA片段化。因此,我们得出结论,凋亡不是塞来昔布治疗的RA FLS中的主要死亡途径。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号